Siemens to work with Tocagen on companion test for Toca cancer therapies
Executive Summary
Siemens Healthcare Diagnostics Inc. is solidifying its decision to enter the companion diagnostics field through a new deal with cancer drug developer Tocagen Inc. in which the partners will design a new test for the latter’s brain cancer candidates Toca 511 and Toca FC.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Therapeutic Drug Monitoring
-
Biotechnology
- Gene Therapy, Cell Therapy
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice